<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Inhibition of nonfunctional Ras

Loading...
Thumbnail Image

Departments

School / College / Institute

Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Nussinov, Ruth

Jang, Hyunbum

Gaponenko, Vadim

Date

Language

Type

Embargo Status

NO

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Intuitively, functional states should be targeted; not nonfunctional ones. So why could drugging the inactive K-Ras4BG12C work—but drugging the inactive kinase will likely not? The reason is the distinct oncogenic mechanisms. Kinase driver mutations work by stabilizing the active state and/or destabilizing the inactive state. Either way, oncogenic kinases are mostly in the active state. Ras driver mutations work by quelling its deactivation mechanisms, GTP hydrolysis, and nucleotide exchange. Covalent inhibitors that bind to the inactive GDP-bound K-Ras4BG12C conformation can thus work. By contrast, in kinases, allosteric inhibitors work by altering the active-site conformation to favor orthosteric drugs. From the translational standpoint this distinction is vital: it expedites effective pharmaceutical development and extends the drug classification based on the mechanism of action. Collectively, here we postulate that drug action relates to blocking the mechanism of activation, not to whether the protein is in the active or inactive state.

Source

Publisher

Elsevier

Citation

item.page.haspartof

Source

Cell Chemical Biology

item.page.ispartofseries

item.page.edition

DOI

10.1016/j.chembiol.2020.12.012

item.page.datauri

item.page.link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators